CClinicalTrials.gg
CompletedNCT03494387VIXIEUpdated Apr 30, 2021

VitamIn and oXygen Interventions and Cardiovascular Events

A Phase 4 interventional study of Oxygen and Antioxidants in Postoperative Cardiac Complication, sponsored by University Hospital Bispebjerg and Frederiksberg. Completed at 4 sites in Denmark. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by University Hospital Bispebjerg and Frederiksberg · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

This study examines the risks and benefits of antioxidants and normal versus high inspiratory oxygen fraction during anaesthesia.

Read the detailed description

Adult patients with risk factors for developing postoperative cardiac complications will be enrolled in the study. The patients will be randomised to receiving antioxidants or placebo perioperatively and 30% or 80% inspiratory oxygen concentration during anaesthesia and 2 hours postoperatively. The primary outcome is MINS (myocardial injury after non-cardiac surgery). The antioxidants are ascorbic acid (vitamin C) 3 grams intravenously preoperatively and N-acetylcysteine 100 milligrams/kilogram body weight intravenous infusion for 4 hours, starting at the same time as anaesthesia.

The study is a long-term follow-up study of the risk of mortality, MI and readmissions performed at 1 year after inclusion of the last patient. Two other follow-up studies are planned: One investigation of ischaemic troponin elevations defined as peak troponin levels above the internationally defined thresholds without extracardiac causes; another investigating the intervention effects in the subgroup of patients undergoing vascular surgery with specific emphasis on episodes of intraoperative hypotension within the following thresholds: MAP below 70 mmHg, 65 mmHg, 60 mmHg and 55 mmHg.

02

Conditions studied

  • Postoperative Cardiac Complication

Browse trials for

Keywords

  • Antioxidant
  • Hyperoxia
  • Troponin
  • MINS
  • Ascorbic acid
  • N-acetylcysteine
03

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

All of the listed criteria (1.-4.) must be met.

  1. Age 45 years or above
  2. Elective or acute surgery in general anaesthesia
  3. Scheduled for abdominal, orthopaedic, or vascular surgery with expected surgery duration of one hour or more.
  4. Fulfil any 1 of the following 5 criteria:

      • History of coronary artery disease including angina
      • History of stroke
      • Undergoing vascular surgery
      • History of peripheral arterial disease
      • Any 2 of the following 8 criteria: i. Acute surgery ii. Current or previous daily smoking iii. History of hypertension iv. Diabetes mellitus requiring medical treatment v. History of transient cerebral ischemia vi. Plasma creatinine >175 µM vii. Age 70 years or above viii. History of congestive heart failure

Exclusion criteria

Exclusion criteria:

  1. Surgery within 30 days prior to operation
  2. Arterial oxygen saturation below 90% without oxygen supplementation
  3. Inability to give informed consent
  4. Drug allergy towards any of the drugs involved in the trial
  5. Previous treatment with bleomycin
  6. Pregnancy
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
600 participants (actual)

Study arms

  • Experimental
    1

    Drug: Oxygen · Drug: Antioxidants

  • Experimental
    2

    Drug: Oxygen · Drug: Antioxidants

Interventions

  • DrugOxygen

    80% versus 30% inspiratory oxygen concentration

  • DrugAntioxidants

    Antioxidants versus placebo

    Also known as: Ascorbic acid, N-acetylcysteine

05

What researchers measure

Primary outcomes

  1. Myocardial injury after non-cardiac surgery (MINS)

    Troponin measurement the first 3 postoperative days. Assessed by area under the curve.

    Time frame: 30 days

Secondary outcomes

  1. Mortality

    Assessed as time to event analysis

    Time frame: During the study period until completion of last visit of last patient

  2. Non-fatal myocardial infarction

    Assessed as time to event analysis

    Time frame: During the study period until completion of last visit of last patient

  3. Non-fatal Serious Adverse Event

    Assessed as time to event analysis

    Time frame: During the study period until completion of last visit of last patient

Other outcomes

  1. Surgical site infection

    Infection in surgical area as defined by the Center for Disease Control

    Time frame: Assessed at postoperative day 30

  2. Pneumonia

    Pneumonia as defined by the Center for Disease Control

    Time frame: Assessed at postoperative day 30

  3. Sepsis

    Sepsis as defined by the joint task force by the European Society of Intensive Care Medicine and the Society of Critical Care Medicine

    Time frame: Assessed at postoperative day 30

  4. Acute respiratory failure

    Acute respiratory failure defined as the need for controlled ventilation or oxygen saturation of 900% or less despite of oxygen therapy

    Time frame: Assessed at postoperative day 30

  5. Acute kidney injury

    Acute kidney injury as defined Kidney Disease Improving Global Outcomes guidelines

    Time frame: Assessed at postoperative day 30

06

Study locations

4 sites
  • Abdominalcentret, Rigshospitalet
    Copenhagen, 2100, Denmark
  • HovedOrtoCentret, Rigshospitalet
    Copenhagen, 2100, Denmark
  • Bispebjerg and Frederiksberg Hospital, University of Copenhagen
    Copenhagen, Denmark
  • Herlev Hospital
    Herlev, Denmark
07

Registry details

Key details

Study ID
NCT03494387
Lead sponsor
University Hospital Bispebjerg and Frederiksberg
Responsible party
Cecilie Petersen (MD, University Hospital Bispebjerg and Frederiksberg) — Principal investigator
First posted
Apr 11, 2018
Start date
Apr 6, 2018
Primary completion
Mar 1, 2020
Completion
Mar 24, 2020
Last update
Apr 30, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion